IBI322
innovent biologics
['hodgkin', 'lymphoma', 'innovent', '$ivbxf']
$ivbxf - innovent announces phase 1 clinical data of ibi322 (cd47/pd-l1 bispecific antibody) in the treatment of anti-pd-(l)1-resistant classic hodgkin lymphoma patients at the eha 2023 annual meeting 
Follow for the latest #healthcare #stockmarket tweets. Visit https://t.co/wA5OfUn0Ee to try our powerful investing tools.